ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension
American Journal of Respiratory Cell and Molecular Biology · 2025
DOI: 10.1165/rcmb.2024-0149oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2025. Verfasst von Adam L Fellows und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute and. Hauptthemen laut MEDLINE: ADP-Ribosylation Factors, Basic Helix-Loop-Helix Proteins, Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
ARF6 (ADP-ribosylation factor 6), a GTPase associated with cancer metastasis, is activated in the lung endothelium in pulmonary arterial hypertension (PAH). To identify ARF6-regulated pathways relevant to PAH, we performed a state-of-the-art proteomic analysis of human pulmonary artery endothelial cells (HPAECs) overexpressing the wild-type, constitutively active, fast-cycling, and dominant-negative mutants of ARF6. The analysis revealed a novel link of ARF6 with HIF (hypoxia-inducible factor), in addition to endocytotic vesicle trafficking, cell proliferation, angiogenesis, oxidative stress, and lipid metabolism. Active ARF6 markedly increased expression and activity of HIF-2, critical in PAH, with HIF-1 relatively unaffected. Hypoxic ARF6 activation was a prerequisite for HIF-2 activation and HIF-dependent gene expression in HPAECs, PAH blood-derived late-outgrowth endothelial colony-forming cells, and hypoxic mouse lungs in vivo. A novel ARF6 inhibitor, chlortetracycline (CTC), reduced hypoxia-induced HIF-2 activation, proliferation, and angiogenesis in HPAECs and reduced HIF-2 expression in lung and heart tissues of hypoxic mice. PAH endothelial colony-forming cells showed elevated expression and activity of ARF6 and HIF2, which was attenuated by CTC, and oral CTC attenuated development of pulmonary hypertension in chronically hypoxic mice. We identify EGFR (epidermal growth factor receptor) as a direct interactor of ARF6 and EGFR signaling as a crucial mechanism linking ARF6 and HIF activation. In conclusion, we are the first to demonstrate a key role of ARF6 in the regulation of HIF-2α activation in vitro and in vivo and show that HIF-2α, a master regulator of vascular remodeling in PAH, can be targeted by a clinically approved antibiotic CTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute and.
- King's British Heart Foundation Centre, King's College London, London, United Kingdom; and.
- Department of Infectious Disease, Imperial College London, London, United Kingdom.
- Francis Crick Institute, London, United Kingdom.
ORCID-Profile: Adam L Fellows, Lan Zhao, Beata Wojciak-Stothard
Förderung
- British Heart Foundation
Zitieren
APA
Fellows, A. L., Chen, C. N., Xie, C., Iyer, N., Schmidt, L., Yin, X., Yates, L. A., Mayr, M., Cowburn, A., Zhao, L., & Wojciak-Stothard, B. (2025). ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2024-0149oc
Vancouver
Fellows AL, Chen CN, Xie C, Iyer N, Schmidt L, Yin X, et al. ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology. 2025. doi:10.1165/rcmb.2024-0149oc
BibTeX
@article{Fellows2025,
author = {Fellows, Adam L and Chen, Chien-Nien and Xie, Chongyang and Iyer, Nayana and Schmidt, Lukas and Yin, Xiaoke and Yates, Luke A and Mayr, Manuel and Cowburn, Andrew and Zhao, Lan and Wojciak-Stothard, Beata},
title = {ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
doi = {10.1165/rcmb.2024-0149oc}
}
EUVIMED